CervoMed (NASDAQ: CRVO) entered definitive agreements for a registered direct offering of 2,500,000 common shares at $4.00 per share, priced at-the-market under Nasdaq rules.Gross proceeds are expected to be $10 million, closing around June 22, 2026, with funds for working capital and general corporate purposes.
Loading…
Loading translation…
AI-generated analysis. Not financial advice.
Positive
Raises approximately $10 million in gross proceeds
Financing priced at-the-market under Nasdaq rules
Net proceeds earmarked for working capital and general corporate purposes
Uses existing effective Form S-3 shelf registration to access capital
Negative
Issuance of 2,500,000 new common shares may dilute existing shareholders
Gross proceeds of $10 million are before agent fees and expenses
Closing remains subject to customary closing conditions, adding execution risk
Shares offered
2,500,000 shares
Common stock in registered direct offering
Offering price
$4.00 per share
Purchase price in registered direct offering
Gross proceeds
$10 million
Expected before fees and expenses from offering
Form S-3 file
File No. 333-282494
Shelf registration statement used for this offering
S-3 effective date
October 10, 2024
SEC effectiveness of shelf registration statement
Short interest
4.99%
Reported as of 2026-05-29 settlement date
Float reference
5,262,331 shares
Shares float used in short-interest context
Major holder ownership
19.99%
Beneficial ownership by Joshua S. Boger per Schedule 13D/A
CRVO showed a large upside move while close peers had mixed, mostly modest moves (small gains, losses or flat), indicating the action appears company-specific rather than a broad biotech sector shift.
Date
Event
Sentiment
Move
Catalyst
Jun 18
Patent allowance
Positive
+73.5%
New U.S. patent extends neflamapimod protection for pure DLB into 2042.
Jun 12
Conference participation
Neutral
-0.4%
Company participation in H.C. Wainwright neuro summit and investor meetings.
Jun 10
Private placement financing
Negative
-22.1%
Private placement raising $10.5M upfront to fund Phase 3 and partnerships.
May 18
Quarterly earnings
Negative
-11.6%
Q1 2026 results with $12.9M cash and $8.0M quarterly net loss reported.
Apr 22
Clinical data update
Positive
+0.8%
RewinD-LB MRI data showed basal forebrain volume and connectivity improvements.
Pattern Detected
Recent history shows strong positive reactions to IP/clinical wins, while financing and earnings updates have typically coincided with downside pressure.
Short Interest
4.99% of shares outstanding
as of 2026-05-29
Days to cover: 2.86
Short interest appears moderate, suggesting some potential for volatility but limited indication of extreme squeeze-driven trading based on current positioning.
This announcement adds $10 million of capital via a registered direct offering priced at-the-market, increasing dilution but bolstering resources for development. Recent history links financings to pressure, while net insider buying and moderate short interest remain important context to watch.
registered direct offering
financial
“entered into definitive agreements for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share in a registered direct offering priced at-the-market”
A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.
at-the-market
financial
“common stock at a purchase price of $4.00 per share in a registered direct offering priced at-the-market under Nasdaq rules”
“At-the-market” is a method for companies to sell new shares of stock directly into the open market over time, rather than all at once. It allows companies to raise money gradually, similar to selling slices of a pie instead of the entire pie at once, which can help manage the sale’s impact on the stock price. This approach gives investors a steady supply of shares while providing companies with flexible funding options.
shelf registration statement
regulatory
“being offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-282494)”
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
form s-3
regulatory
“pursuant to a “shelf” registration statement on Form S-3 (File No. 333-282494) that was declared effective”
Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.
prospectus supplement
regulatory
“The offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.”
A prospectus supplement is an additional document provided alongside a company’s main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
AI-generated analysis. Not financial advice.
See more from StockTitan in Google Search and AI answers.
Adds StockTitan as a preferred source · opens Google
06/18/2026 – 12:35 PM
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has entered into definitive agreements for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about June 22, 2026, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering are expected to be $10 million, before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. The common stock described above are being offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-282494) that was declared effective by the Securities and Exchange Commission (SEC) on October 10, 2024. The offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, New York 10022, by phone at (212) 856-5711 or e-mail at [email protected]. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About CervoMed CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with dementia with Lewy bodies (DLB), enriched for those without Alzheimer’s disease co-pathology, and the Company announced alignment with the US Food and Drug Administration (FDA) on a potential registration path for neflamapimod in DLB in November 2025. Initiation of a Phase 3 trial in DLB is subject to the establishment of a partnership and/or additional financing. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nonfluent variant primary progressive aphasia, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026 Forward-Looking Statements This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to: the timing, size and expectation of the closing of the offering; and expectations regarding market conditions, the satisfaction of customary closing conditions related to the offering and the anticipated use of proceeds therefrom. Terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “aims,” “seeks,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential,” “target,” “project,” “contemplate,” “predict,” “forecast,” “continue,” or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company’s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the satisfaction of the closing conditions to and consummation of the offering; the Company’s available cash resources, the availability of additional funds on acceptable terms or at all, and the Company’s ability to continue as a going concern; the results of the Company’s clinical trials; the Company’s ability to successfully enter into a partnership to advance neflamapimod into Phase 3 for DLB in a timely manner, on acceptable terms, or at all; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA or other regulators; the Company’s ability to maintain the intellectual property protection afforded by the Company’s patent portfolio; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 13, 2026, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law. Contacts Media:Lisa GuitermanBiongage [email protected] Investor Relations:Argot [email protected]
FAQ
What did CervoMed (NASDAQ: CRVO) announce on June 18, 2026 about a stock offering?
CervoMed announced a registered direct offering of 2,500,000 common shares at $4.00 per share. According to CervoMed, the deal is priced at-the-market under Nasdaq rules and is expected to generate $10 million in gross proceeds before fees and expenses.
How much money will CervoMed (CRVO) raise from its June 2026 registered direct offering?
CervoMed expects to raise approximately $10 million in gross proceeds from the offering. According to CervoMed, this is based on selling 2,500,000 common shares at a purchase price of $4.00 per share, before deducting placement agent fees and other offering expenses.
When is the CervoMed (CRVO) $10 million registered direct offering expected to close?
The offering is expected to close on or about June 22, 2026. According to CervoMed, completion of the transaction depends on the satisfaction of customary closing conditions typically required for this type of registered direct financing.
How will CervoMed use the proceeds from the June 2026 CRVO stock offering?
CervoMed plans to use the net proceeds for working capital and general corporate purposes. According to CervoMed, funds from the $10 million registered direct offering will support ongoing operations rather than being earmarked for a specific acquisition or single project.
What type of financing structure is CervoMed (CRVO) using for the June 2026 capital raise?
CervoMed is using a registered direct offering priced at-the-market under Nasdaq rules. According to CervoMed, the common shares are issued under an effective Form S-3 shelf registration statement, with H.C. Wainwright & Co. acting as exclusive placement agent.
Does the June 2026 CervoMed (CRVO) stock offering dilute existing shareholders?
The offering increases the number of common shares outstanding, which may dilute existing shareholders’ ownership percentages. According to CervoMed, 2,500,000 new common shares will be issued in this registered direct transaction to raise approximately $10 million in gross proceeds.
